Stephen Walsh

Assistant Professor

Brigham and Women's Hospital

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Stephen Walsh is an Assistant Professor at Brigham and Women's Hospital in the United States. His research focuses on the evaluation and development of mRNA vaccines, as highlighted in his recent publications, which include studies on HIV-1 vaccines and COVID-19 vaccine effectiveness. He is also engaged in pharmacokinetics and safety assessments of monoclonal antibodies, contributing to advancements in treatments for both infectious diseases and conditions with limited therapeutic options.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

UNITED STATES

View details

Jenny Hendriks

Head Biomarkers

Janssen (Netherlands)

NETHERLANDS

View details

Yunda Huang

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Paul Goepfert

The University of Alabama

UNITED STATES

View details

Margaret Yacovone

National Institutes of Health

UNITED STATES

View details

Evan Anderson

Emory University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stephen Walsh

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial

Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data

High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost.

Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants

Immunogenicity of quadrivalent meningococcal conjugate vaccine in frequent platelets donors.

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials

Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study

Collaborators (13)

Kathryn Stephenson

Andrew Fiore-Gartland

Jesse Clark

Kenneth Mayer

Alison Roxby

Caryn Morse

Thomas Martin

Kristen W Cohen

Jenny Hendriks

Yunda Huang

Paul Goepfert

Margaret Yacovone

Evan Anderson

Make your next move.